These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1968207)

  • 1. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation.
    Rapold HJ
    Lancet; 1990 Feb; 335(8687):481-2. PubMed ID: 1968207
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinogen proteolysis and coagulation system activation during thrombolytic therapy.
    Owen J; Grossman B; Sobel J; Kudryk B
    Adv Exp Med Biol; 1990; 281():401-8. PubMed ID: 2129378
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.
    Rapold HJ; Kuemmerli H; Weiss M; Baur H; Haeberli A
    Circulation; 1989 May; 79(5):980-9. PubMed ID: 2496939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
    Rapold HJ; de Bono D; Arnold AE; Arnout J; De Cock F; Collen D; Verstraete M
    Circulation; 1992 Mar; 85(3):928-34. PubMed ID: 1537129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary thrombolysis, conjunctive heparin infusion, and the effect on systemic thrombin activity.
    Garabedian HD; Gold HK
    Circulation; 1992 Mar; 85(3):1205-7. PubMed ID: 1537116
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase.
    Rapold HJ; Grimaudo V; Declerck PJ; Kruithof EK; Bachmann F
    Blood; 1991 Sep; 78(6):1490-5. PubMed ID: 1832058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.
    Owen J; Friedman KD; Grossman BA; Wilkins C; Berke AD; Powers ER
    Blood; 1988 Aug; 72(2):616-20. PubMed ID: 3135862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.
    Merlini PA; Bauer KA; Oltrona L; Ardissino D; Spinola A; Cattaneo M; Broccolino M; Mannucci PM; Rosenberg RD
    J Am Coll Cardiol; 1995 Jan; 25(1):203-9. PubMed ID: 7798503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of fibrinopeptide A in patients treated with phenprocoumon.
    Harenberg J; Haas R; Zimmermann R
    Thromb Haemost; 1981 Jun; 45(3):282-4. PubMed ID: 7281107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Abe S; Takahashi E; Handa S; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Angiology; 1994 Apr; 45(4):273-81. PubMed ID: 8161005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial design in the thrombolytic age.
    Bahr RD
    Lancet; 1991 Mar; 337(8741):610-1. PubMed ID: 1671959
    [No Abstract]   [Full Text] [Related]  

  • 12. Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
    Wang Y; Liu Q; Zhu J; Yuan Z; Ma X
    Chin Med Sci J; 2002 Mar; 17(1):36-9. PubMed ID: 12894883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of lipoprotein (a) in thrombolysis with r-TPA for myocardial infarction].
    Santos Filho RD; Tranchesi Júnior B; Caramelli B; Barbosa V; Gebara O; de Albuquerque CP; Vinagre C; Maranhão R; Pileggi F
    Arq Bras Cardiol; 1991 Jul; 57(1):9-12. PubMed ID: 1823766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GUSTO trial: is the open-artery hypothesis proven?
    Stringer KA; Lindenfeld J
    Ann Pharmacother; 1994 Jan; 28(1):97-8. PubMed ID: 8123971
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombolytic therapy for myocardial infarction.
    Guerci AD
    Md Med J; 1990 Apr; 39(4):377-81. PubMed ID: 2110282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.
    Bailey AL; Steinhubl SR
    CMAJ; 2006 May; 174(10):1431-2. PubMed ID: 16682711
    [No Abstract]   [Full Text] [Related]  

  • 18. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.
    Weitz JI; Cruickshank MK; Thong B; Leslie B; Levine MN; Ginsberg J; Eckhardt T
    J Clin Invest; 1988 Nov; 82(5):1700-7. PubMed ID: 3141481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators.
    Califf RM; Topol EJ
    Clin Cardiol; 1992 Mar; 15(3):143-4. PubMed ID: 1551260
    [No Abstract]   [Full Text] [Related]  

  • 20. Coronary thrombolysis: round two and beyond.
    Wilcox RG
    Br Heart J; 1991 Apr; 65(4):175-6. PubMed ID: 1903042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.